Wird geladen...
Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
BACKGROUND: Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always...
Gespeichert in:
| Veröffentlicht in: | Leuk Res |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8190959/ https://ncbi.nlm.nih.gov/pubmed/28843161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2017.08.002 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|